Outcomes on Quality of Life, Weight Loss, and Comorbidities After Roux-en-Y Gastric Bypass

Abstract

Context Bariatric surgery has become the most effective method for producing weight loss in obese patients. The evaluation of improvement of comorbidities and changes in the quality of life are important outcome factors; however, it is necessary to investigate whether they persist over the long term. Methods A cross-sectional study was conducted on 143 obese patients from our institution from February 2007 to February 2008. These patients were divided into five independent groups, one being a control group, plus four other groups with 1, 2, 3, 4 or more years following surgical Roux-en-Y gastric bypass with a silicon ring banded. quality of life forms and anthropometric measurements were performed and its scores correlated with social factors, weight loss success, and status of obesity-related conditions. Results For the group that was 1 year postoperative, a significant percentage of excess body weight loss (EBWL%) of 81.7% was observed. The groups with 2, 3, 4 or more years of post-surgical follow-up showed a EBWL decline, but without significant difference. The main comorbidity percentages in all patients who had the surgery was as follows: 69.7% for hypertension; 88.2% for diabetes mellitus; and 27.5% for arthropathy. There was a significant decrease in the rate for diabetes resolution (P = 0.035) observed by evolutionary assessment of the comorbidity resolution. The results obtained by BAROS were good, very good, or excellent in more than 96% of patients in all evaluations that were performed. The use of the Moorehead-Ardelt Questionnaire (M/A) demonstrated improvement in the quality of life. Moreover, the quality of life, when evaluated through SF-36, also showed improvement in all related areas after 1 year; however, after 4 years, improvement remained elevated only in the areas of general state of health and functional capacity. Conclusions The Roux-en-Y gastric bypass procedure was able to achieve EBWL of 81.7% after 1 year following surgery, remaining steady with little decline after this period. Important resolution of comorbidities, such as hypertension and diabetes, was also seen. Immediate surgical outcomes assessed by SF-36 and M/A in the area of quality of life were satisfactory, but the general state of health and functional capacity areas were sustained satisfactory at a later time only.

Perceived oral health in patients after bariatric surgery using oral health‐related quality of life measures

“…Obesity may contribute to the occurrence of various health conditions such as diabetes mellitus, cardiovascular disease, stroke, hypertension, and certain cancer forms (Marsicano, Sales‐Peres, Ceneviva, & de Sales‐Peres, ; Vairavamurthy, Cheskin, Kraitchman, Arepally, & Weiss, ; Vinciguerra et al, ) and associates with oral health problems such as dental caries, periodontitis, and hyposalivation (Marsicano, Sales‐Peres, Ceneviva, & de Sales‐Peres, ). Bariatric surgery is considered to be one of the most effective and a safe method to achieve weight loss in adults and may improve systemic conditions (Barbosa et al, ; Costa, Yamaguchi, Santo, Riccioppo, & Pinto‐Junior, ). However, bariatric surgery may also have negative impact on oral health conditions because of an increase in periodontal disease, caries, and dental wear (de Moura‐Grec et al, ; Heling et al, ).…”

Validation of a new method for the endoscopic measurement of post-bariatric gastric outlet using a standard guidewire: an observer agreement study

“…Although bariatric surgery procedures effectively treat morbid obesity and reduce rates of long-term obesity-related complications [1, 2], weight regain might occur in up to 20% of all patients. Among a multitude of possible factors associated with weight regain, gastric outlet dilation occurs when its diameter exceeds 14–20 mm, ultimately leading patients back to obesity [3].…”

Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity

“…However, adverse effects of some and the transient weight losses associated with others[27] mean that the pharmacological management of obesity remains suboptimal. The only proven treatment to achieve and maintain weight loss in obesity is bariatric surgery[28-30]. However, surgical and anaesthetic risks associated with overweight and obese status sees these invasive procedures reserved to those patients classed morbidly obese (BMI ≥ 40 kg/m 2 ) or as a last resort in those failing more conservative management[20,31,32].…”